SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 287.21 |
| Enterprise Value ($M) | 148.19 |
| Book Value ($M) | 326.04 |
| Book Value / Share | 3.73 |
| Price / Book | 0.88 |
| NCAV ($M) | 324.48 |
| NCAV / Share | 3.72 |
| Price / NCAV | 0.89 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.28 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.38 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 30.89 |
| Current Ratio | 30.89 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 337.75 |
| Assets | 339.31 |
| Liabilities | 13.27 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -101.87 |
| Net Income | -88.85 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -70.02 |
| Cash from Investing | -12.41 |
| Cash from Financing | 164.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Deep Track Capital, LP | 6.39 | -8.58 | |
| 13G/A | Schonfeld Strategic Advisors LLC | 4.93 | -17.75 | |
| 13G | Morgan Stanley | 8.10 | ||
| 13G/A | Citadel Advisors Llc | 4.10 | ||
| 13G/A | Soleus Capital Master Fund, L.P. | 9.60 | 30.83 | |
| 13G/A | BlackRock, Inc. | 6.80 | 22.23 | |
| 13G/A | Vivo Capital Fund VIII, L.P. | 5.40 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 4.99 | -21.80 | |
| 13G/A | Fairmount Funds Management LLC | 0.00 | -100.00 | |
| 13G/A | Suvretta Capital Management, Llc | 0.00 | -100.00 | |
| 13G/A | Point72 Asset Management, L.P. | 3.50 | -26.19 | |
| 13G/A | Integrated Core Strategies (us) Llc | 1.90 | -53.20 | |
| 13D/A | Orbimed Advisors Llc | 9.00 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 238,920 | 638,389 | 37.43 | |
| 210,309 | 656,233 | 32.05 | |
| 167,517 | 491,456 | 34.09 | |
| 128,200 | 450,454 | 28.46 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SYRE – Spyre Therapeutics, Inc. | TARS – Tarsus Pharmaceuticals, Inc. |
| TECH – Bio-Techne Corporation | TLRY – Tilray Brands, Inc. |
| TNYA – Tenaya Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io